WT1 Dendritic Cell Vaccine Therapy Improves Immune Profile and Prolongs Progression-Free Survival in End-Stage Lung Cancer

被引：4
|
作者：
Nagai, Hisashi [1 ,2 ]
Karube, Ryusuke [1 ]
机构：
[1] Ginza Phoenix Clin, Oncol, Tokyo, Japan
[2] Tokai Univ, Grad Sch Human & Environm Studies, Tokyo, Japan
来源：
CUREUS JOURNAL OF MEDICAL SCIENCE | 2023年 / 15卷 / 10期
关键词：
wt1; progression-free survival; chemotherapy response; cancer immunotherapy; immune profile; metastatic non-small cell lung cancer; dendritic cell; MEDIATED CYTOTOXICITY; IMMUNOTHERAPY; NEUTROPHIL;
D O I：
10.7759/cureus.47320
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
WT1-pulsed dendritic cell (WT1-DC) therapy was performed for end-stage squamous cell lung cancer that rapidly worsened soon after completion of carboplatin and paclitaxel. A rapid improvement in immune profile was observed with the initiation of WT1-DC. Docetaxel and ramucirumab were initiated as second -line agents during WT1-DC. The improvement of the immune profile status continued, and at the same time, the cancer showed a predominant shrinkage. Progression-free survival was over 577 days, and the patient was able to lead a normal daily life with a performance status of 1. These findings suggest that WT1-DC improves the immune profile, and this may contribute to the long-lasting and sustained effect of chemotherapy.
引用
收藏
页数：6
相关论文
共 50 条
  • [41] Tumor Response and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Extensive Stage Small-Cell Lung Cancer Findings on the Basis of North Central Cancer Treatment Group Trials
    Foster, Nathan R.
    Qi, Yingwei
    Shi, Qian
    Krook, James E.
    Kugler, John W.
    Jett, James R.
    Molina, Julian R.
    Schild, Steven E.
    Adjei, Alex A.
    Mandrekar, Sumithra J.
    CANCER, 2011, 117 (06) : 1262 - 1271
  • [42] Machine learning analysis of pathological images to predict 1-year progression-free survival of immunotherapy in patients with small-cell lung cancer
    Shibaki, Ryota
    Fujimoto, Daichi
    Nozawa, Tsukasa
    Sano, Akira
    Kitamura, Yuka
    Fukuoka, Junya
    Sato, Yuki
    Kijima, Takashi
    Matsumoto, Hirotaka
    Yokoyama, Toshihide
    Miura, Satoru
    Hata, Akito
    Tamiya, Motohiro
    Taniguchi, Yoshihiko
    Sugisaka, Jun
    Furuya, Naoki
    Tanaka, Hisashi
    Yamamoto, Nobuyuki
    Koh, Yasuhiro
    Akamatsu, Hiroaki
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (02)
  • [43] A radiomics prognostic scoring system for predicting progression-free survival in patients with stage Ⅳ non-small cell lung cancer treated with platinum-based chemotherapy
    Lan He
    Zhenhui Li
    Xin Chen
    Yanqi Huang
    Lixu Yan
    Changhong Liang
    Zaiyi Liu
    Chinese Journal of Cancer Research, 2021, 33 (05) : 592 - 612
  • [44] Clinicopathological Factors Affecting Progression-Free Survival of Patients With Previously Treated Advanced Non-Small Cell Lung Cancer After S-1 Therapy With or Without Bevacizumab
    Masago, Katsuhiro
    Fujita, Shiro
    Hata, Akito
    Kaji, Reiko
    Ohtsuka, Kyoko
    Okuda, Chiyuki
    Takeshita, Jumpei
    Katakami, Nobuyuki
    ANTICANCER RESEARCH, 2014, 34 (12) : 7467 - 7472
  • [45] Humoral Immune Responses to EGFR-Derived Peptides Predict Progression-Free and Overall Survival of Non-Small Cell Lung Cancer Patients Receiving Gefitinib
    Azuma, Koichi
    Komatsu, Nobukazu
    Hattori, Satoshi
    Matsueda, Satoko
    Kawahara, Akihiko
    Sasada, Tetsuro
    Itoh, Kyogo
    Hoshino, Tomoaki
    PLOS ONE, 2014, 9 (01):
  • [46] Chinese Medicine Combined With EGFR-TKIs Prolongs Progression-Free Survival and Overall Survival of Non-small Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations, Compared With the Use of TKIs Alone
    Wang, Yujia
    Wu, Guoyu
    Li, Ru
    Luo, Yingzhe
    Huang, Xingmei
    He, Lifang
    Zhong, Huihui
    Xiong, Shaoquan
    FRONTIERS IN PUBLIC HEALTH, 2021, 9
  • [47] Correlating the effects of VeriStrat result, anti-PD1 therapy, and neutrophil-to-lymphocyte ratio (NLR) on progression-free survival (PFS) in patients with stage IV non-small cell lung cancer (NSCLC).
    Randall, Megan
    Basu, Sanjib
    Batus, Marta
    Borgia, Jeffrey Allen
    Bonomi, Philip D.
    Fidler, Mary J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [48] Association between Tumor Heterogeneity and Progression-free Survival in Non-small Cell Lung Cancer Patients with EGFR Mutations Undergoing Tyrosine Kinase Inhibitors Therapy
    Song, Jiangdian
    Dong, Di
    Huang, Yanqi
    Zang, Yali
    Liu, Zaiyi
    Tian, Jie
    2016 38TH ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY (EMBC), 2016, : 1268 - 1271
  • [49] SIMULATION AND COMPARISON OF PROGRESSION-FREE SURVIVAL (PFS) AMONG PATIENTS WITH NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) RECEIVING SEQUENTIAL THERAPY
    Chouaid, C.
    Walzer, S.
    Lister, J.
    Gultyaev, D.
    Vergnenegre, A.
    de Marinis, F.
    Meng, J.
    de Castro, J.
    Crott, R.
    Kleman, M.
    Ngoh, C. A.
    VALUE IN HEALTH, 2014, 17 (03) : A70 - A70
  • [50] A radiomics prognostic scoring system for predicting progression-free survival in patients with stage IV non-small cell lung cancer treated with platinum-based chemotherapy
    He, Lan
    Li, Zhenhui
    Chen, Xin
    Huang, Yanqi
    Yan, Lixu
    Liang, Changhong
    Liu, Zaiyi
    CHINESE JOURNAL OF CANCER RESEARCH, 2021, 33 (05) : 592 - +
12345